文献速递消化内镜消化道肿瘤与早癌

MC-003溶液用于内镜下黏膜或黏膜下切除的疗效与安全性:一项前瞻性、多中心、随机、三盲、平行组III期研究

Efficacy and safety of MC-003 solution for endoscopic mucosal or submucosal resection: a prospective, multicenter, randomized, triple-blinded, parallel-group, phase III study.
PubMed 文献 · Gastrointest Endosc · 2024-01-04

这项前瞻性、多中心、随机、三盲、平行组III期研究比较了新型海藻酸钠基溶液MC-003与生理盐水(NS;0.9%氯化钠)在内镜下黏膜切除或内镜黏膜下剥离术中的疗效与安全性,最终每组各34例患者。MC-003组在整块切除中需要额外注射的次数更少,尤其对于大于15 mm的病变、位于胃远端部位的病变以及在内镜黏膜下剥离术过程中,且不增加严重不良事件的发生率。

要点

  • MC-003组在病变>15 mm、胃远端部位及内镜黏膜下剥离术中需额外注射更少。
  • 两组不良事件发生率相当。

核心结论

  • MC-003在整块切除中减少额外注射需求方面优于生理盐水,尤其对于位于胃远端部位(大多数病变所在部位)的较大病变及在内镜黏膜下剥离术过程中,且不增加严重不良事件的发生率。
  • MC-003是一种在真实临床环境中很有前景的黏膜下注射溶液。

研究设计与样本

  • 前瞻性、多中心、随机、三盲、平行组III期研究。
  • 最初纳入70例计划接受内镜下黏膜切除或内镜黏膜下剥离术的患者。
  • 最终每组各纳入34例患者。

主要发现

  • 所有患者均实现整块切除(P=1.000)。
  • MC-003组有更多瘤周组织纤维化(P=.056)。
  • MC-003组对于>15 mm的病变需要更少的额外注射(P=.037)。
  • MC-003组对于位于胃远端部位的病变需要更少的额外注射(P=.007)。
  • MC-003组在内镜黏膜下剥离术过程中需要更少的额外注射(P=.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The safety and efficacy of solutions for submucosal injection are critical for endoscopic resection of gastric adenomas or early gastric cancers. Although several injectable solutions have been introduced for endoscopic resection, they have some limitations. We aimed to compare the efficacy of the new sodium alginate-based solution MC-003 with that of normal saline (NS; 0.9% sodium chloride). METHODS: In this randomized, triple-blind study, 70 patients were initially enrolled for EMR or endoscopic submucosal dissection (ESD). The main outcomes included the need for additional injections, completion of en bloc resection, and occurrence of adverse events. RESULTS: Each group ultimately included 34 patients. Complete en bloc resections were achieved in all patients (P = 1.000). The MC-003 group had more peri-neoplasm tissue fibrosis (P = .056) and needed fewer additional injections for lesions >15 mm (P = .037), located in the distal portion of the stomach (P = .007), and during ESD procedures (P = .001). The adverse event rate was comparable in both groups. CONCLUSIONS: MC-003 outperformed NS in reducing the need for additional injections during en bloc resection, particularly in larger lesions located in the distal portion of the stomach (where most lesions were found) during ESD procedures, without increasing the incidence of serious adverse events. MC-003 is a promising submucosal injectable solution in real-world clinical settings.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Lee AY, Jang JY, Seo JY, et al. Efficacy and safety of MC-003 solution for endoscopic mucosal or submucosal resection: a prospective, multicenter, randomized, triple-blinded, parallel-group, phase III study. Gastrointest Endosc. 2024. PMID: 38184114. doi:10.1016/j.gie.2024.01.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。